AssetMark Inc’s Revance Therapeutics, Inc. RVNC Stock Holding History

AssetMark Inc’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-68	Closed	-$335	–	2259
2024 Q1	$335	Sell	68 -1,978	-97%	-$11.7K	﹤0.01%	1758
2023 Q4	$18K	Sell	2,046 -1,211	-37%	-$9.92K	﹤0.01%	1308
2023 Q3	$37.4K	Buy	3,257 +1,261	+63%	+$24.2K	﹤0.01%	1154
2023 Q2	$50.5K	Buy	+1,996	New	+$62.2K	﹤0.01%	1077
2016 Q1	–	Sell	-14	Closed	–	–	1441
2015 Q4	$0	Buy	+14	New	+$485	﹤0.01%	1498

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AssetMark Inc's RVNC Position: Q2 2024 in Review

AssetMark Inc sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 68 shares — an estimated $335 sold.

AssetMark Inc first reported a position in RVNC in Q4 2015 and held it in 5 quarters. The position peaked at $50.5K in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

AssetMark Inc reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
AssetMark Inc sold 68 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $335.
AssetMark Inc first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
AssetMark Inc's Revance Therapeutics, Inc. position peaked at $50.5K in Q2 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on AssetMark Inc's 13F filing for Q2 2024, filed 13 Aug 2024.